Education
About Us
Working with TipRanks
Follow Us
ABVC BioPharma, Inc. (ABVC)
NASDAQ:ABVC
Total Valuation
ABVC BioPharma has a market cap or net worth of $31.42M. The enterprise value is $244.55M.
Market Cap$31.42M
Enterprise Value$244.55M
Share Statistics
ABVC BioPharma has 16,981,592 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding16,981,592
Owned by Insiders―
Owned by Institutions0.07%
Financial Efficiency
ABVC BioPharma’s return on equity (ROE) is -4.00 and return on invested capital (ROIC) is -166.20%.
Return on Equity (ROE)-4.00
Return on Assets (ROA)-0.65
Return on Invested Capital (ROIC)-166.20%
Return on Capital Employed (ROCE)-4.79
Revenue Per Employee31.85K
Profits Per Employee-328.69K
Employee Count16
Asset Turnover0.07
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ABVC BioPharma is -1.49. ABVC BioPharma’s PEG ratio is 1.68.
PE Ratio-1.49
PS Ratio0.00
PB Ratio-1.59K
Price to Fair Value5.97
Price to FCF-76.60
Price to Operating Cash Flow-76.60
PEG Ratio1.68
Income Statement
In the last 12 months, ABVC BioPharma had revenue of 509.59K and earned -4.90M in profits. Earnings per share was -0.43.
Revenue509.59K
Gross Profit508.83K
Operating Income-4.71M
Pretax Income-5.37M
Net Income-4.90M
EBITDA-4.34M
Earnings Per Share (EPS)-0.43
Cash Flow
In the last 12 months, operating cash flow was -1.63M and capital expenditures 0.00, giving a free cash flow of -1.88M billion.
Operating Cash Flow-1.63M
Free Cash Flow-1.88M
Free Cash Flow per Share-0.11
Dividends & Yields
ABVC BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.76
52-Week Price Change126.92%
50-Day Moving Average1.22
200-Day Moving Average0.76
Relative Strength Index (RSI)63.69
Average Volume (3m)309.07K
Important Dates
ABVC BioPharma upcoming earnings date is Nov 17, 2025, TBA Not Confirmed.
Last Earnings DateMar 28, 2025
Next Earnings DateNov 17, 2025
Ex-Dividend Date―
Financial Position
ABVC BioPharma as a current ratio of 0.33, with Debt / Equity ratio of -3033.44%
Current Ratio0.33
Quick Ratio0.33
Debt to Market Cap0.24
Net Debt to EBITDA-0.50
Interest Coverage Ratio-5.70
Taxes
In the past 12 months, ABVC BioPharma has paid -111.00K in taxes.
Income Tax-111.00K
Effective Tax Rate0.02
Enterprise Valuation
ABVC BioPharma EV to EBITDA ratio is -2.19, with an EV/FCF ratio of -5.25.
EV to Sales18.67
EV to EBITDA-2.19
EV to Free Cash Flow-5.25
EV to Operating Cash Flow-5.25
Balance Sheet
ABVC BioPharma has $217.26K in cash and marketable securities with $2.17M in debt, giving a net cash position of $1.95M billion.
Cash & Marketable Securities$217.26K
Total Debt$2.17M
Net Cash$1.95M
Net Cash Per Share$0.12
Tangible Book Value Per Share$0.06
Margins
Gross margin is 97.13%, with operating margin of -924.73%, and net profit margin of -963.57%.
Gross Margin97.13%
Operating Margin-924.73%
Pretax Margin-1055.29%
Net Profit Margin-963.57%
EBITDA Margin-853.49%
EBIT Margin-892.97%
Analyst Forecast
The average price target for ABVC BioPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast1904.43%
EPS Growth Forecast93.72%